Acs infectious diseases - Latest News Update, Information, Photos & Videos on Acs infectious diseases at Lokmat Times

Florida [US], June 24 : Because the disease is becoming increasingly resistant to existing medications, a group of UCF researchers is attempting to use cancer pharmaceuticals to accelerate the development of new, life-saving malaria treatments.The study's findings were published in the journal ACS Infectious Diseases.Malaria, one of the world's most common infectious diseases, is a potentially fatal condition caused by Plasmodium species parasites and spread through the bite of infected mosquitoes. It kills over 600,000 people each year, mostly in Sub-Saharan Africa. Approximately 80 percent of these fatalities involve children under the age of five."Over time, genetic mutation of the malaria parasite makes it resistant to current drugs," Chakrabarti says."The World Health Organization reported that malaria parasites are increasingly becoming resistant to the current therapy used to treat malaria, which was discovered in the 1990s. So, new and more effective drugs for malaria are long overdue as about 30 years have gone by since we have had a new class of compounds in the market against malaria."But drug discoveries can take years, even decades, Chakrabarti explained, as compounds go through many phases of testing for efficacy and safety."One of the ways we can accelerate the discovery of new treatment options is to use existing drugs that are already approved by the Food and Drug Administration," Chakrabarti said. "This is called taking a piggyback approach, looking at existing drugs that are already on the market to see if they have anti-malarial properties. This will help to shorten the initial stages of drug discovery which is usually quite time-consuming."To meet the urgent need for new drugs, the team decided to repurpose protein kinase inhibitors drugs originally developed for cancer treatment for an accelerated path to drug therapy for malaria. Protein kinases are enzymes that regulate proteins in the body and are heavily targeted for cancer and other disease therapies by the pharmaceutical industry. Protein kinases are very important for the malaria parasite's life cycle and as such make good drug targets.As part of the study, PhD candidate Monica Bohmer, working under Chakrabarti's supervision, tested a range of anti-cancer protein kinase inhibitors to identify inhibitors that are known to target human Polo-like kinase, a type of protein kinase that plays a vital role in cell division in humans. She discovered that a group of inhibitors, specifically BI-2536, a known human Polo-like kinase 1 inhibitor, exhibited strong anti-malarial properties."While the malaria parasite plasmodium does not have Polo-like kinases, the protein kinase inhibitors targeted another family of proteins called NEK, which also regulate cell division," Bohmer says. "They also targeted other stress-response pathways which helped to kill the parasite."She added that future studies will explore the functions of these NEK proteins in the parasite."Overall, this study provides valuable insights for the potential of repurposing of protein kinase inhibitors for malaria treatment," Chakrabarti said "while also underscores the need for further research to identify additional targets and optimize the efficacy of these inhibitors."Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Narendra Modi

Lok Sabha Election 2024

Heatwave In India

Mumbai Mega Block

Maharashtra Lok Sabha Election

T20 World Cup 2024

Acs Infectious DiseasesFOLLOW

Acs infectious diseases, Latest News

Health :Malaria treatment made possible by cancer medication: Study

Florida [US], June 24 : Because the disease is becoming increasingly resistant to existing medications, a group of UCF ... ...